Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Licenses Gene Variants from Pathway Diagnostics for Dx Predicting Drug Response

NEW YORK, March 22 (GenomeWeb News) - Nanogen has licensed genetic variations from Pathways Diagnostics that predict patients' response to antidepressants and antipsychotic in order to create a diagnostic product, the company said today.


Under the non-exclusive agreement, the companies have been working on a molecular diagnostic product, based on Nanogen's NanoChip platform, to determine the appropriate drug dosage for patients with psychiatric disorders. Nanogen plans to include Pathways' gene variations along with cytochrome P450 family members.


The companies did not disclose financial details of the agreement.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.